Product Description
Mechanisms of Action: Imaging Agent, avb6
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Zhongnan Hospital
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Pancreatic Cancer|Head and Neck Cancer|Breastfeeding|Colorectal Cancer|Drug Hypersensitivity|Hypersensitivity, Delayed|Nut Hypersensitivity|Neuromyelitis Optica|NUT Carcinoma|Lung Cancer|Contraception|Male Breast Cancer|Pregnancy Outcomes|Liver Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07420036 |
SFB6-ZN01 PET | P1 |
Not yet recruiting |
Breastfeeding|Head and Neck Cancer|Nut Hypersensitivity|Hypersensitivity, Delayed|Liver Cancer|Male Breast Cancer|Colorectal Cancer|Drug Hypersensitivity|NUT Carcinoma|Neuromyelitis Optica|Pregnancy Outcomes|Contraception|Pancreatic Cancer|Lung Cancer |
2028-12-31 |
2026-02-20 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|